Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab

Medicine and Dentistry

• Epidermal Growth Factor Receptor 87%
• Mutant 50%
• Cetuximab 25%
• Panitumumab 25%
• Patient 25%
• In Vitro 12%
• Predictor 12%
• Combination Therapy 12%
• Receptor 12%
• Somatic Mutation 12%
• Ligand 12%
• Screening 12%
• Colorectal Cancer 12%
• Colorectal Carcinoma 12%
• Colon Cancer 12%
• Monoclonal Antibody 12%
• Anti-Epidermal Growth Factor Receptor 12%
• Chemotherapeutic Agent 12%
• Metastatic Colorectal Cancer 12%
• Drug 12%
• Cell Transformation 12%
• Epidermal Growth Factor Receptor Antibody 12%
• Cells 12%

Biochemistry, Genetics and Molecular Biology

• Epidermal Growth Factor Receptor 100%
• Mutant 50%
• Mutation 37%
• Cetuximab 25%
• Panitumumab 25%
• Dimerization 12%
• Electric Potential 12%
• Screening 12%
• Monoclonal Antibody 12%
• Cell Transformation 12%
• Somatic Mutation 12%
• Taxonomy 12%
• Colon 12%
• Antibody 12%

Chemistry

• Epidermal Growth Factor 100%
• Mutation 50%
• Oncogenic 37%
• Ligand 12%
• Chemical Transformation 12%
• Monoclonals 12%
• Potential 12%
• Dimerization 12%